Moderna Inc. Stock

According to some new data revealed by Moderna (NASDAQ: MRNA) at the American Association for Cancer Research Annual Meeting on April 8, the biotech responsible for the Spikevax coronavirus vaccine

For many, Moderna (NASDAQ: MRNA) stock is yesterday's news. The stock earned a great deal of attention during the coronavirus pandemic, as it was one of the early developers of a vaccine to fight

Before the COVID-19 pandemic, most investors likely hadn't heard of Moderna (NASDAQ: MRNA). At the end of 2019, it was a relatively small biotech company with only collaboration and grant revenue

Moderna (NASDAQ: MRNA) shot to stardom in the early days of the pandemic as it brought its coronavirus vaccine from drawing board to commercialization in less than a year -- and then went on to

It's always possible to come up with a justification for why someone should sell their shares of a stock, but that doesn't make every justification correct. For a company like Moderna (NASDAQ: MRNA)

Moderna (NASDAQ: MRNA) was a top stock to own during the early stages of the pandemic. The COVID-19 vaccine maker reached a market cap of nearly $200 billion at its peak in 2021. But nowadays, with

The past four years have been a roller-coaster ride for Moderna (NASDAQ: MRNA). The mRNA-focused vaccine maker rose to prominence following a successful attempt at developing a coronavirus vaccine.

You can find growth stocks in every sector. With healthcare making up nearly one-fifth of the U.S. economy, it's a great place to look.

Three Motley Fool contributors have identified what they think

Regarding Moderna (NASDAQ: MRNA) stock, RBC Capital analyst Luca Issi is bullish. Per his price target of $125 that he reiterated on Feb. 23, the biotech's shares could rise by 30% to reach $125

Image source: The Motley Fool.

Moderna (NASDAQ: MRNA)Q4 2023 Earnings CallFeb 22, 2024, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Shares of Moderna (NASDAQ: MRNA) were jumping 9.5% higher as of 11:09 a.m. ET on Thursday after rising as much as 10% earlier in the day. The gain came after the biotech company announced its

There's arguably no better time to buy a stock than when it's been beaten down. Doing so provides a reasonable entry point for investors willing to hold the stock for a while, which can translate to

Moderna (NASDAQ: MRNA) shares skyrocketed in the early stages of the pandemic as the biotech company became one of the first to bring a vaccine to market. That vaccine went on to generate billions

Growth stocks are supposed to, well, grow. That's especially the expectation when the overall stock market soars as it did in 2023.

However, even the best growth stocks can experience rough patches

Moderna (NASDAQ: MRNA) was one of the hottest stocks to own during the rollout of COVID-19 vaccines a few years ago. These days, however, the hype has cooled off significantly. The company is facing

The pandemic has receded substantially, and with it, the need for vaccines and medicines against COVID-19. That's not to say we no longer need them -- just a lot less so than we did in the earlier

Moderna (NASDAQ: MRNA) once was one of the stock market's biggest stars. The biotech stock surged more than 400% back in 2020 as it brought a coronavirus vaccine from drawing board to market in less

The stock market has been picking up steam of late amid hopes of interest rate cuts and a soft landing for the economy in 2024. Should that happen, stocks could be on track for a great year. And

On Dec. 14, Moderna (NASDAQ: MRNA) and Merck (NYSE: MRK) jointly reported some great news for patients as well as investors: A powerful new cancer therapy is in the works, and the freshly published

Moderna (NASDAQ: MRNA) today is known for its one and only product: the coronavirus vaccine now known as Spikevax. But the company has big goals, aiming to launch as many as 15 new products over the

Cathie Wood favors companies that innovate and have what it takes to become tomorrow's winners. But she won't buy them at just any price. The superstar investor will only pick up shares of these

Moderna (NASDAQ: MRNA), a star stock during the pandemic era, continues to struggle in a world that seems to be moving past COVID-19. According to data compiled by S&P Global Market Intelligence

After its dim third-quarter earnings report on Nov. 2, Moderna (NASDAQ: MRNA) saw its shares crash by more than 12% before recovering. Still, the stock is down by 60% this year, and it's clear that

Superstar investor Cathie Wood doesn't flinch when she sees a declining stock price. In fact, Wood keeps her cool and often invests in struggling stocks -- as long as the particular company has a

Shares of Moderna (NASDAQ: MRNA) recently did some bouncing around. The company posted results on the morning of Nov. 2, and the stock lost more than 10% when the market opened. Luckily, positive